Shimada Yuka, Oda Yasunori, Shibata Shintaro, Hirose Yuki, Sasaki Tsuyoshi
Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, JPN.
Department of Child Psychiatry, Chiba University Hospital, Chiba, JPN.
Cureus. 2024 Jan 29;16(1):e53182. doi: 10.7759/cureus.53182. eCollection 2024 Jan.
We describe a 32-year-old Japanese female with hypersomnia and bipolar disorder. She had developed hypersomnia and sleep attacks in her teens. She was misdiagnosed with narcolepsy at a neurology department and then received methylphenidate (MPH) for many years. After giving birth, she developed postpartum depression and suffered from mood swings and irritability. Following 10-year treatment with methylphenidate, she experienced MPH-induced psychosis when she was in a manic state. Her psychosis improved rapidly with the cessation of methylphenidate. Furthermore, brexpiprazole treatment ameliorated her manic symptoms and hypersomnolence. Post-discharge, she was diagnosed with idiopathic hypersomnia based on nocturnal polysomnography and a multiple sleep latency test. This case indicates that brexpiprazole as a serotonin dopamine activity modulator might provide therapeutic effects against not only the patient's manic symptoms but also idiopathic hypersomnia.
我们描述了一位患有发作性睡病和双相情感障碍的32岁日本女性。她在青少年时期就出现了发作性睡病和睡眠发作症状。她在神经内科被误诊为发作性睡病,随后多年来一直服用哌甲酯(MPH)。产后,她患上了产后抑郁症,并出现情绪波动和易怒症状。在接受了10年的哌甲酯治疗后,她在躁狂状态下出现了MPH诱发的精神病症状。停用哌甲酯后,她的精神病症状迅速改善。此外,布雷哌唑治疗改善了她的躁狂症状和发作性睡病症状。出院后,根据夜间多导睡眠图和多次睡眠潜伏期测试,她被诊断为特发性发作性睡病。该病例表明,作为5-羟色胺多巴胺活性调节剂的布雷哌唑不仅可能对患者的躁狂症状有治疗作用,而且对特发性发作性睡病也有治疗作用。